Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 339 followers
Latest posts
Last updated 1 day ago
Skye and Redx form new entity with $125M to advance fibrosis assets
1 day ago
Skye Bioscience has entered into an agreement to combine with privately held...
‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discovery
1 day ago
BioCryst CEO Charlie Gayer told Fierce the company is “not getting away...
Capricor soars on plan to amend DMD filing after adcomm setback
1 day ago
Capricor Therapeutics has bounced back from a bruising FDA advisory committee meeting...
Chutes & Ladders—Former Legend CEO lands at K2
1 day ago
Just weeks after Legend Biotech announced the departure of its CEO, Ying...
MapLight dims preclinical programs to make phase 3-ready schizophrenia drug shine brighter
2 days ago
Despite mixed results for its experimental schizophrenia treatment last month, MapLight Therapeutics...
Building Resilience for the Future of Biopharma Innovation
2 days ago
How can industry build resilience as science advances? WuXi AppTec Co-CEO Dr...
PDS halts work on phase 3 cancer therapy to focus on colorectal contender
3 days ago
PDS Biotechnology has called time on its phase 3 head and neck...
After tasting IPO success, Hemab’s CEO seeks ‘flavor of a multi-product coagulation company’
3 days ago
With the post-IPO quiet period having come to an end, CEO Benny...
PTC’s $211M bid wins Sangamo auction, teeing up ‘special opportunity’ to enter Fabry market
3 days ago
PTC Therapeutics has struck a deal to buy Sangamo Therapeutics’ Fabry disease...
Medtronic veteran Bill Shields crosses over to become CEO at valve disease startup
3 days ago
After 15 years with Medtronic’s structural heart franchise, Bill Shields is leaving...
Pfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pill
3 days ago
Three years after Robert Hoffman sold XinThera to Gilead, the veteran Pfizer...
Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goal
3 days ago
Taiho Pharmaceutical and Cullinan Therapeutics have celebrated a second phase 3 victory...